GAP Australasian-Dentist-Mar Apr 2019

False and misleading conduct by AFT Pharmaceuticals (AU) Pty Ltd The Federal Court has found that AFT Pharmaceuticals (AU) Pty Ltd (AFT) engaged in false and misleading conduct through its Maxigesic advertising campaign. This follows legal action by RECKITT BENCKISER (AUSTRALIA) PTY LIMITED. From about March 2017 AFT published an advertising campaign in pamphlets and later in magazines and cards for its Maxigesic over-the-counter analgesic. The Federal Court found that AFT engaged in misleading conduct under the Australian Consumer Law when it represented that: (i) Maxigesic provides stronger and more effective relief from all pain than Nuromol when taken at their respective maximum recommended daily doses; (ii) When taken at their respective maximum recommended daily doses, Maxigesic provides stronger and more effective relief from pain than any other paracetamol/ibuprofen combination (iii) When taken at their respective maximum recommended daily doses, Maxigesic provides stronger and more effective relief from pain than OTC doses of either paracetamol or ibuprofen alone (iv) Maxigesic reduces pain by at least 32% more than a full daily OTC dose of either paracetamol or ibuprofen alone throughout the period of administration of either drug; (v) there was a current adequate foundation in scientific knowledge for each of the representations set out in subparagraphs (i) to (iv) above For further information contact AFT Pharmaceuticals Pty Ltd, Sydney on 1800 2387 4276 or by email on receptionau@aftpharm.com CORRECTIVE NOTICE Published by order of the Federal Court of Australia